Your browser doesn't support javascript.
loading
IMMUNOGENICITY AND IMPACT ON NASOPHARYNGEAL CARRIAGE OF A SINGLE DOSE OF PCV10 GIVEN TO VIETNAMESE CHILDREN AT 18 MONTHS OF AGE.
Higgins, Rachel A; Temple, Beth; Dai, Vo Thi Trang; Phan, Thanh V; Toan, Nguyen Trong; Spry, Leena; Toh, Zheng Quan; Nation, Monica L; Ortika, Belinda D; Uyen, Doan Y; Cheung, Yin Bun; Nguyen, Cattram D; Bright, Kathryn; Hinds, Jason; Balloch, Anne; Smith-Vaughan, Heidi; Huu, Tran Ngoc; Mulholland, Kim; Satzke, Catherine; Licciardi, Paul V.
Affiliation
  • Higgins RA; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Australia.
  • Temple B; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Australia.
  • Dai VTT; Global Health, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
  • Phan TV; Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
  • Toan NT; Microbiology and Immunology, Pasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Spry L; Microbiology and Immunology, Pasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Toh ZQ; Department of Disease Control and Prevention, Pasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Nation ML; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Australia.
  • Ortika BD; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Australia.
  • Uyen DY; Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
  • Cheung YB; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Australia.
  • Nguyen CD; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Australia.
  • Bright K; Department of Disease Control and Prevention, Pasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Hinds J; Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore.
  • Balloch A; Centre for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland.
  • Smith-Vaughan H; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Australia.
  • Huu TN; Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
  • Mulholland K; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Australia.
  • Satzke C; Institute for Infection and Immunity, St George's, University of London, London, UK.
  • Licciardi PV; BUGS Bioscience, London Bioscience Innovation Centre, London, UK.
Lancet Reg Health West Pac ; 16: 100273, 2021 Nov.
Article in En | MEDLINE | ID: mdl-34590071
ABSTRACT

BACKGROUND:

This study investigated the immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to 18-month-old Vietnamese children. This information is important for countries considering catch-up vaccination during PCV introduction and in the context of vaccination during humanitarian crises.

METHODS:

Two groups of PCV-naïve children within the Vietnam Pneumococcal Project received PCV10 (n=197) or no PCV (unvaccinated; n=199) at 18 months of age. Blood samples were collected at 18, 19, and 24 months of age, and nasopharyngeal swabs at 18 and 24 months of age. Immunogenicity was assessed by measuring serotype-specific IgG, opsonophagocytosis (OPA) and memory B cells (Bmem). Pneumococci were detected and quantified using real-time PCR and serotyped by microarray.

FINDINGS:

At 19 months of age, IgG and OPA responses were higher in the PCV10 group compared with the unvaccinated group for all PCV10 serotypes and cross-reactive serotypes 6A and 19A. This was sustained out to 24 months of age, at which point PCV10-type carriage was 60% lower in the PCV10 group than the unvaccinated group. Bmem levels increased between 18 and 24 months of age in the vaccinated group.

INTERPRETATION:

We demonstrate strong protective immune responses in vaccinees following a single dose of PCV10 at 18 months of age, and a potential impact on herd protection through a substantial reduction in vaccine-type carriage. A single dose of PCV10 in the second year of life could be considered as part of catch-up campaigns or in humanitarian crises to protect children at high-risk of pneumococcal disease.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Lancet Reg Health West Pac Year: 2021 Type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Lancet Reg Health West Pac Year: 2021 Type: Article Affiliation country: Australia